论文部分内容阅读
阿糖胞苷(Ara-C)于1959年合成,是细胞周期特异性抗肿瘤药物,1968年应用于临床,被广泛应用于白血病及其他恶性肿瘤的化学治疗。上世纪80年代开始广泛用于儿童急性白血病的治疗,迄今已有30余年的历史。普通剂量的阿糖胞苷治疗儿童急性白血病不良反应轻微,耐受性较好。而在90年代提出的中、大剂量阿糖胞苷化疗方案,提高了治疗的缓解率,但也增加了不良反应的发生,现将我科应用中剂量阿糖胞苷治疗儿童急性淋巴细胞白血病不良反应总结如下。
Cytarabine (Ara-C) was synthesized in 1959. It is a cell cycle-specific anti-tumor drug. It was used clinically in 1968 and is widely used in the chemotherapy of leukemia and other malignant tumors. The 1980s has been widely used in the treatment of childhood acute leukemia, so far, more than 30 years of history. Common doses of cytarabine treatment of acute leukemia in children with mild adverse reactions, better tolerated. And in the 90’s, medium and large doses of cytarabine chemotherapy to improve the treatment of remission rate, but also increased the incidence of adverse reactions, now we apply mid-dose of cytarabine treatment of children with acute lymphoblastic leukemia Adverse reactions summarized as follows.